The FDA-NIMH-MATRICS Guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
Open accessAbstract
The Food and Drug Administration (FDA)-National Institute of Mental Health (NIMH)-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) clinical trial guidelines for cognitive-enhancing drugs in schizophrenia and the MATRICS Consensus Cognitive Battery (MCCB) were designed to facilitate novel compound development in the treatment of cognitive impairments. Several studies have recently utilized the FDA-NIMH-MATRICS guidelines and MCCB and allow an evaluation of the feasibility of guideline implementation and MCCB performance. In light of the study results, we would recommend the following inclusion criteria revisions-(1) clinical status and symptom inclusion criteria: maximum allowed score for hallucinations and delusions should be increased from moderate to moderately severe and the negative symptom criterion should be dropped in phase 2 studies; (2) antipsychotic medication inclusion criteria: first-generation antipsychotics should be allowed, but only in the context of no concomitant anticholinergic agents and minimal extrapyramidal symptoms, and antipsychotic polypharmacy should be allowed in the absence of pertinent pharmacokinetic or pharmacodynamic considerations; and (3) people who use illicit substances should not be allowed in phase 1B or 2A proof-of-concept studies but may be included in phase 2B and 3 studies in which proof of effectiveness and generalizability of results become more important goals. These revisions are recommended to enhance recruitment while maintaining sufficient methodological rigor to ensure the validity of study results. The MCCB has been shown to have excellent psychometric characteristics, including reliability for multisite clinical trials, clinical relevance for real-world functioning, and possible sensitivity to behavioral treatment, and should continue to serve as the standard outcome measure for cognitive enhancement studies in schizophrenia.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Based on experience from early studies that used the MATRICS clinical trial guidelines, the MATRICS investigators recommended revision of the inclusion criteria to enhance recruitment while maintaining sufficient methodological rigor.
“Based on experience from early studies that used the MATRICS clinical trial guidelines, the MATRICS investigators recommended revision of the inclusion criteria to enhance recruitment while maintaining sufficient methodological rigor.20”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [20]
The MATRICS recommendation for a phase 3 registration trial to be at least 6 months remained unchanged in the recent revision.
“The original MATRICS guidelines17 specify that a phase 3 registration trial should be of sufficient duration to show an enduring effect on cognition (ie, at least 6 months), and this recommendation remained unchanged in their recent revision.20”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516 · see citing works
Self-citationThe MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., Essock, S., Fenton, W. S., Frese, F. J., Gold, J. M., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010042 · Cited by 2,342 · see citing works
Self-citationLongitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
Green, M. F., Kern, R. S., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.009 · Cited by 1,422 · see citing works
Self-citationKahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088 · see citing works
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,072 · see citing works
Self-citationGreen, M. F., Nuechterlein, K. H., Gold, J. M., Barch, D. M., Cohen, J., Essock, S., Fenton, W. S., Frese, F., Goldberg, T. E., Heaton, R. K., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.023 · Cited by 919 · see citing works
Self-citationMilev, P., Ho, B., Arndt, S. V., & Andreasen, N. C. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.495 · Cited by 919 · see citing works
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization
Kern, R. S., Nuechterlein, K. H., Green, M. F., Baade, L. E., Fenton, W. S., Gold, J. M., Keefe, R. S. E., Mesholam-Gately, R., Mintz, J., Seidman, L. J., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010043 · Cited by 744 · see citing works
Self-citationPatterson, T., Goldman, S., McKibbin, C. L., Hughs, T., & Jeste, D. V. (2001) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006870 · Cited by 740 · see citing works
A Separate Disease Within the Syndrome of Schizophrenia
Kirkpatrick, B. W., Buchanan, R. W., Ross, D. E., & Carpenter, W. T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.2.165 · Cited by 651 · see citing works
Self-citationBuchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438 · see citing works
Self-citationUsing Neuroplasticity-Based Auditory Training to Improve Verbal Memory in Schizophrenia
Fisher, M., Holland, C. M., Merzenich, M. M., & Vinogradov, S. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08050757 · Cited by 428 · see citing works
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426 · see citing works
Self-citationGoldberg, T. E., GOLDMAN, R. S., Burdick, K. E., Malhotra, A. K., Lencz, T., Patel, R. C., Woerner, M. G., Schooler, N. R., Kane, J. M., & Robinson, D. G. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1115 · Cited by 396 · see citing works
Keefe, R. S. E., Poe, M. P., Walker, T. M., Kang, J. W., & Harvey, P. D. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.426 · Cited by 396 · see citing works
Self-citationDevelopment of a Brief Scale of Everyday Functioning in Persons with Serious Mental Illness
Mausbach, B. T., Harvey, P. D., Goldman, S. R., Jeste, D. V., & Patterson, T. L. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm014 · Cited by 381 · see citing works
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377 · see citing works
Davidson, M., Galderisi, S., Weiser, M., Werbeloff, N., Fleischhacker, W., Keefe, R. S. E., Boter, H., Keet, I. P. M., Prelipceanu, D., RYBAKOWSKI, J. K., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08060806 · Cited by 320 · see citing works
Self-citationKeefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Lewine, R. R. J., Yurgelun-Todd, D. A., Gur, R. C., Tohen, M., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.985 · Cited by 314 · see citing works
Self-citationMishara, A. L., & Goldberg, T. E. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.027 · Cited by 308 · see citing works
Green, M. F., Nuechterlein, K. H., Kern, R. S., Baade, L. E., Fenton, W. S., Gold, J. M., Keefe, R. S. E., Mesholam‐Gately, R. I., Seidman, L. J., Stover, E. S., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010089 · Cited by 236 · see citing works
Self-citationGanguly, R., Kotzan, J. A., Miller, L. S., Kennedy, K., & Martin, B. C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1013 · Cited by 227 · see citing works
Evaluation of social problem solving in schizophrenia.
Bellack, A. S., Sayers, M. D., Mueser, K. T., & Bennett, M. (1994) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.103.2.371 · Cited by 222 · see citing works
Vinogradov, S., Fisher, M., Warm, H., Holland, C. M., Kirshner, M. A., & Pollock, B. G. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09010017 · Cited by 220 · see citing works
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone
Green, M. F., Marder, S. R., Glynn, S. M., McGurk, S. R., Wirshing, W. C., Wirshing, D. A., Liberman, R. P., & Mintz, J. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01370-7 · Cited by 201 · see citing works
Self-citationMarx, C. E., Keefe, R. S. E., Buchanan, R. W., Hamer, R. M., Kilts, J. D., Bradford, D. W., Strauss, J. L., Naylor, J. C., Payne, V. M., Lieberman, J. A., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.26 · Cited by 193 · see citing works
Self-citationEvaluation of social problem solving in schizophrenia.
Bellack, A. S., Sayers, M. D., Mueser, K. T., et al. (1994) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.103.2.371 · Cited by 172 · see citing works
Galantamine for the treatment of cognitive impairments in people with schizophrenia
Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., & McMahon, R. P. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050724 · Cited by 170 · see citing works
Self-citationNeuropsychology of the Deficit Syndrome: New Data and Meta-analysis of Findings To Date
Cohen, A. S., Saperstein, A. M., Gold, J. M., Kirkpatrick, B., Carpenter, W. T., & Buchanan, R. W. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl066 · Cited by 163 · see citing works
Self-citationHarvey, P. D., Rabinowitz, J., Eerdekens, M., & Davidson, M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1888 · Cited by 161 · see citing works
Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial
Chakos, M., Glick, I. D., Miller, A. L., Hamner, M. B., Miller, D. D., Patel, J. K., Tapp, A. M., Keefe, R. S. E., & Rosenheck, R. A. (2006) · Psychiatric Services · doi:10.1176/appi.ps.57.8.1094 · Cited by 117 · see citing works
Self-citationChakos, M., Glick, I. D., Miller, A. L., Hamner, M. B., Miller, D. D., Patel, J. K., Tapp, A. M., Keefe, R. S. E., & Rosenheck, R. A. (2006) · Psychiatric Services · doi:10.1176/ps.2006.57.8.1094 · Cited by 116 · see citing works
Self-citationAntipsychotic medication coprescribing in a large state hospital system
Jaffe, A. B., & Levine, J. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.783 · Cited by 111 · see citing works
Direct assessment of functional abilities: relevance to persons with schizophrenia
McKibbin, C. L., Brekke, J. S., SIRES, D. A., Jeste, D. V., & Patterson, T. L. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.011 · Cited by 109 · see citing works
Long-term combination antipsychotic treatment in VA patients with schizophrenia
Kreyenbuhl, J. A., Valenstein, M. M., McCarthy, J. F., Ganoczy, D. A., & Blow, F. C. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.02.023 · Cited by 84 · see citing works
Ventura, J., Cienfuegos, A., Boxer, O., & Bilder, R. M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.07.025 · Cited by 80 · see citing works
LAUGHREN, T. P., & Levin, R. L. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi039 · Cited by 79 · see citing works
Self-citationMcEvoy, J. P. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.164.7.1050 · Cited by 77 · see citing works
The reliability and validity of the Test of Adaptive Behavior in Schizophrenia (TABS)
Velligan, D. I., Diamond, P., Glahn, D. C., Ritch, J., Maples, N. J., Castillo, D., & Miller, A. L. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2006.10.007 · Cited by 50 · see citing works
New Paradigms for Treatment Development
Stover, E. L., Brady, L. S., & Marder, S. R. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm085 · Cited by 20 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Keefe R, Siu C, Fox K, et al. Test-Retest characteristics of the MATRICS Consensus Cognitive Battery in a 20-site schizo- phrenia clinical trial of R3487/MEM3454 versus placebo. Schizophr Bull. 2009;35:358-359.
Cited by
Sorted by citations
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292 · see citing works
Cognitive Impairment in Schizophrenia
Keefe, R. S. E., & Harvey, P. D. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_2 · Cited by 497 · see citing works
Self-citationTargeting the correct HDAC(s) to treat cognitive disorders
Fischer, A., Sananbenesi, F., Mungenast, A. E., & Tsai, L. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.003 · Cited by 355 · see citing works
Millan, M. J., Fone, K. C. F., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 354 · see citing works
Social Cognition Psychometric Evaluation: Results of the Initial Psychometric Study
Pinkham, A. E., Penn, D. L., Green, M. F., & Harvey, P. D. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv056 · Cited by 303 · see citing works
Self-citationNielsen, R. E., Levander, S. E., Telléus, G. K., Jensen, S. O. W., Christensen, T. Ø., & Leucht, S. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12374 · Cited by 269 · see citing works
Carbon, M., & Correll, C. U. (2014) · CNS Spectrums · doi:10.1017/s1092852914000601 · Cited by 258 · see citing works
Keefe, R. S. E., Fox, K. H., Harvey, P. D., Cucchiaro, J., Siu, C., & Loebel, A. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.09.015 · Cited by 237 · see citing works
Self-citationThe treatment of cognitive impairment in schizophrenia
GOFF, D. C., Hill, M. B., & Barch, D. M. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.11.009 · Cited by 196 · see citing works
Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review
Bortolato, B., Carvalho, A., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130203823 · Cited by 181 · see citing works
The MATRICS Consensus Cognitive Battery in Patients with Bipolar I Disorder
Burdick, K. E., Goldberg, T. E., Cornblatt, B. A., Keefe, R. S. E., Gopin, C. B., DeRosse, P., Braga, R. J., & Malhotra, A. K. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.36 · Cited by 181 · see citing works
Self-citationBuchanan, R. W., Keefe, R. S. E., Lieberman, J. A., Barch, D. M., Csernansky, J. G., Goff, D. C., Gold, J. M., Green, M. F., Jarskog, L. F., Javitt, D. C., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.052 · Cited by 172 · see citing works
Self-citationPrimary and persistent negative symptoms: Concepts, assessments and neurobiological bases
Mucci, A., Merlotti, E., Üçok, A., Aleman, A., & Galderisi, S. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.05.014 · Cited by 141 · see citing works
Baune, B. T., Brignone, M., & Larsen, K. G. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx070 · Cited by 140 · see citing works
Keefe, R. S. E., Buchanan, R. W., Marder, S. R., Schooler, N. R., Dugar, A., Zivkov, M., & Stewart, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr153 · Cited by 138 · see citing works
Self-citationFleischhacker, W. W., Podhorná, J., Groeschl, M., Hake, S., Zhao, Y., Huang, S., Keefe, R. S. E., Desch, M., Brenner, R., Walling, D. P., et al. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30513-7 · Cited by 137 · see citing works
Self-citationHoriguchi, M., Huang, M., & Meltzer, H. Y. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180638 · Cited by 123 · see citing works
Millan, M. J., & Bales, K. L. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.09.012 · Cited by 116 · see citing works
Javitt, D. C., Buchanan, R. W., Keefe, R. S. E., Kern, R. S., McMahon, R. P., Green, M. F., Lieberman, J. A., GOFF, D. C., Csernansky, J. G., McEvoy, J. P., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.001 · Cited by 118 · see citing works
Self-citationKeefe, R. S. E., Vinogradov, S., Medalia, A. A., Buckley, P. F., Caroff, S. N., D’Souza, D. C., Harvey, P. D., Graham, K. A., Hamer, R. M., Marder, S., et al. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07100 · Cited by 97 · see citing works
Self-citationEuropean Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia
Vita, A., Gäebel, W., Mucci, A., Sachs, G., Erfurth, A., Barlati, S., Zanca, F., Giordano, G. M., Glenthøj, L. B., Nordentoft, M., et al. (2022) · European Psychiatry · doi:10.1192/j.eurpsy.2022.2316 · Cited by 99 · see citing works
Advancing Translational Research Using NIMH Research Domain Criteria and Computational Methods
Sanislow, C. A., Ferrante, M., Pacheco, J. L., Rudorfer, M. V., & Morris, S. E. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.024 · Cited by 93 · see citing works
Horiguchi, M., & Meltzer, H. Y. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2561-4 · Cited by 89 · see citing works
Validation of a Computerized test of Functional Capacity
Keefe, R. S. E., Davis, V. G., Atkins, A. S., Vaughan, A. W., Patterson, T., Narasimhan, M., & Harvey, P. D. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.03.038 · Cited by 82 · see citing works
Self-citationVelligan, D. I., Roberts, D. L., Mintz, J., Maples, N. J., Li, X., Medellin, E. M., & Brown, M. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.04.008 · Cited by 80 · see citing works
Burdick, K. E., Ketter, T. A., Goldberg, J. F., & Calabrese, J. R. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14cs09399 · Cited by 75 · see citing works
Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale
Keefe, R. S. E., Davis, V. G., Spagnola, N. B., Hilt, D. C., Dgetluck, N., Ruse, S. A., Patterson, T. D., Narasimhan, M., & Harvey, P. D. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.06.009 · Cited by 72 · see citing works
Self-citationJeon, D.-W., Jung, D.-U., Kim, S.-J., Shim, J.-C., Moon, J., Seo, Y.-S., Jung, S. S., Seo, B.-J., Kim, J., Oh, M., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.12.009 · Cited by 69 · see citing works
Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia
Marx, C. E., Lee, J., Subramaniam, M., Rapisarda, A., Bautista, D., Chan, E. S., Kilts, J. D., Buchanan, R. W., Eu, P. W., Verma, S. K., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3673-4 · Cited by 64 · see citing works
Self-citationPhillips, K., Aldridge, J., Ribi, K., Sun, Z., Thompson, A. M., Harvey, V. J., Thurlimann, B. J. K., Cardoso, F., Pagani, O., Coates, A. S., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1235-y · Cited by 63 · see citing works
The developmental course of executive functioning in schizophrenia
Freedman, D., & Brown, A. S. (2010) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2010.11.003 · Cited by 61 · see citing works
Cognitive Enhancement in Schizophrenia
Harvey, P. D., & Bowie, C. R. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.06.008 · Cited by 60 · see citing works
Muscarinic Receptor Activators as Novel Treatments for Schizophrenia
Paul, S. M., Yohn, S. E., Brannan, S. K., Neugebauer, N. M., & Breier, A. F. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.03.014 · Cited by 61 · see citing works
Horisawa, T., Nishikawa, H., Toma, S., Ikeda, A., Horiguchi, M., Ono, M., Ishiyama, T., & Taiji, M. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.01.026 · Cited by 58 · see citing works
Keefe, R. S. E., Fox, K. H., Davis, V. G., Kennel, C., Walker, T. M., Burdick, K. E., & Harvey, P. D. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.05.002 · Cited by 57 · see citing works
Self-citationHoran, W. P., Sauder, C. L., Harvey, P. D., Ramsay, I. S., Yohn, S. E., Keefe, R. S. E., Davis, V. G., Paul, S. M., & Brannan, S. K. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240076 · Cited by 55 · see citing works
Self-citationEgan, M. F., Zhao, X., Gottwald, R., Mozley, L. H., Zhang, Y., Snavely, D. B., Lines, C., & Michelson, D. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.02.030 · Cited by 56 · see citing works
Wu, L., Caprihan, A., Bustillo, J., Mayer, A. R., & Calhoun, V. D. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.06.024 · Cited by 57 · see citing works
Leucht, S., Siafis, S., McGrath, J. J., McGorry, P. D., Howes, O. D., Tamminga, C. A., Carr, R., Bighelli, I., Schneider‐Thoma, J., Priller, J., et al. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00667-6 · Cited by 63 · see citing works
Placebo Response and Practice Effects in Schizophrenia Cognition Trials
Keefe, R. S. E., Davis, V. G., Harvey, P. D., Atkins, A. S., Haig, G. M., HAGINO, O. R., Marder, S. R., Hilt, D. C., & Umbricht, D. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1574 · Cited by 52 · see citing works
Self-citationRossell, S. L., Francis, P. S., Galletly, C. A., Harris, A. W. F., Siskind, D. J., Berk, M., Bozaoglu, K., Dark, F. L., Dean, O. M., Liu, D., et al. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1030-3 · Cited by 49 · see citing works
Zhou, Y., Rosenheck, R., Mohamed, S., Zhang, J., Chang, Q., Ou, Y., Sun, B., Ning, Y., & He, H. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.009 · Cited by 47 · see citing works
Fisher, M., Nahum, M., Howard, E., Rowlands, A., Brandrett, B. D., Kermott, A., Woolley, J. D., & Vinogradov, S. (2017) · Psychiatric Rehabilitation Journal · doi:10.1037/prj0000244 · Cited by 47 · see citing works
Shao, T., Huang, J., Zhao, Y., Wang, W., Tian, X., Hei, G., Kang, D., Gao, Y., Liu, F., Zhao, J., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02616-x · Cited by 45 · see citing works
Millan, M. J., Rivet, J., & Gobert, A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116672342 · Cited by 45 · see citing works
Horiguchi, M., Hannaway, K. E., Adelekun, A. E., Jayathilake, K., & Meltzer, H. Y. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.64 · Cited by 44 · see citing works
Yoshida, T., Suga, M., Arima, K., Muranaka, Y., Tanaka, T., Eguchi, S., Lin, C., Yoshida, S., Ishikawa, M., Higuchi, Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020469 · Cited by 43 · see citing works
Huang, X., Ding, W., Wu, F., Zhou, S., Deng, S., & Ning, Y. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s239763 · Cited by 43 · see citing works
Recio-Barbero, M., Segarra, R., Zabala, A., González–Fraile, E., González-Pinto, A. M., & Ballesteros, J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.631589 · Cited by 40 · see citing works
Knott, V., de la Salle, S., Choueiry, J., Impey, D., Smith, D., Smith, M. K., Beaudry, E., Saghir, S., Ilivitsky, V., & Labelle, A. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.02.004 · Cited by 41 · see citing works
Gilleen, J., Michalopoulou, P. G., Reichenberg, A., Drake, R., Wykes, T., Lewis, S. W., & Kapur, S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.01.001 · Cited by 39 · see citing works
Free thyroxine levels are associated with cognitive abilities in subjects with early psychosis
Barbero, J. D., Gutiérrez‐Zotes, A., Montalvo, I., Creus, M., Cabezas, Á., Solé, M., Algora, M. J., García–Parés, G., Vilella, E., & Labad, J. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.04.030 · Cited by 39 · see citing works
van Duinen, M. A., Reneerkens, O. A. H., Lambrecht, L., Sambeth, A., Rutten, B. P. F., van Os, J., Blokland, A., & Prickaerts, J. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150605110941 · Cited by 39 · see citing works
O’Reilly, K., O'Connell, P., Donohoe, G. J., Coyle, C., O’Sullivan, D., Azvee, Z., Maddock, C., Sharma, K., Sadi, H., McMahon, M., et al. (2016) · Psychological Medicine · doi:10.1017/s0033291716002154 · Cited by 39 · see citing works
Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia
Fervaha, G., Hill, C. L., Agid, O., Takeuchi, H., Foussias, G., Siddiqui, I., Kern, R. S., & Remington, G. J. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.05.015 · Cited by 34 · see citing works
Lam, J. W. S., Lui, S. S. Y., Wang, Y., Chan, R. C. K., & Cheung, E. F. C. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.04.010 · Cited by 34 · see citing works
Greek, R., & Hansen, L. A. (2013) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2013.06.002 · Cited by 33 · see citing works
Belgaied, W., Samp, J. C., Vimont, A., Rémuzat, C., Aballéa, S., Hammi, E. E., Kooli, A., Toumi, M., & Akhras, K. S. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.11.001 · Cited by 33 · see citing works
Reliability and Validity of the CogState Battery Chinese Language Version in Schizophrenia
Zhong, N., Jiang, H., Wu, J., Chen, H., Lin, S., Zhao, Y. F., Du, J., Ma, X., Chen, C., Gao, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074258 · Cited by 33 · see citing works
Effectiveness of Cerebellar Circuitry Modulation in Schizophrenia: A Systematic Review
Escelsior, A., Belvederi Murri, M., Calcagno, P., Cervetti, A., Caruso, R., Croce, E., Grassi, L., & Amore, M. (2019) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000001064 · Cited by 32 · see citing works
A Kiosk Station for the Assessment of Multiple Cognitive Domains and Cognitive Enrichment of Monkeys
Womelsdorf, T., Thomas, C., Neumann, A. R., Watson, M. R., Boroujeni, K. B., Hassani, S. A., Parker, J. M., & Hoffman, K. L. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.721069 · Cited by 30 · see citing works
de Bruin, N. M. W. J., Drimmelen, M. V., Kops, M. S., van Elk, J., de Wetering, M. M.-V., & Schwienbacher, I. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.01.035 · Cited by 31 · see citing works
Sumiyoshi, C., Takaki, M., Okahisa, Y., Patterson, T. L., Harvey, P. D., & Sumiyoshi, T. (2014) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2014.08.002 · Cited by 31 · see citing works
An Update on Treatment of Cognitive Impairment Associated with Schizophrenia
Horan, W. P., Catalano, L. T., & Green, M. F. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_382 · Cited by 31 · see citing works
Self-citationOlivier, M. R., Killian, S., Chiliza, B., Asmal, L., Schoeman, R., Oosthuizen, P., Kidd, M., & Emsley, R. A. (2015) · Psychological Medicine · doi:10.1017/s0033291715000860 · Cited by 31 · see citing works
Interaction Analysis and Cognitive Infocommunications
Vogel, C. M., & Esposito, A. A. (2020) · Híradástechnika/Infocommunications journal · doi:10.36244/icj.2020.1.1 · Cited by 30 · see citing works
Mahncke, H. W., Kim, S., Rose, A., Stasio, C., Buckley, P. F., Caroff, S. N., Duncan, E., Yasmin, S., Jarskog, L. F., Lamberti, J. S., et al. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.03.006 · Cited by 30 · see citing works
Self-citationEnhancing Neuroplasticity to Augment Cognitive Remediation in Schizophrenia
Jahshan, C. S., Rassovsky, Y., & Green, M. F. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00191 · Cited by 29 · see citing works
Self-citationKoola, M. M., Looney, S. W., Hong, H., Pillai, A., & Hou, W. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113285 · Cited by 29 · see citing works
The MATRICS Consensus Cognitive Battery: An Update
Nuechterlein, K. H., Green, M. F., & Kern, R. S. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_395 · Cited by 29 · see citing works
Self-citationHoriguchi, M., & Meltzer, H. Y. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.03.027 · Cited by 28 · see citing works
Bucci, P., Piegari, G., Mucci, A., Merlotti, E., Chieffi, M., Riso, F. D., Angelis, M. D., Munzio, W. D., & Galderisi, S. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.053 · Cited by 28 · see citing works
Pietrzak, R. H., Snyder, P. J., & Maruff, P. T. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.09.012 · Cited by 28 · see citing works
Garay, R. P., Citrome, L., Samalin, L., Liu, C., Thomsen, M. S., Correll, C. U., Hameg, A., & Llorca, P. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1149164 · Cited by 28 · see citing works
Koola, M. M. (2018) · Complex Psychiatry · doi:10.1159/000494495 · Cited by 28 · see citing works
Tarazi, F. I., & Neill, J. C. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.738193 · Cited by 28 · see citing works
Development of a Virtual Reality Assessment of Everyday Living Skills
Ruse, S. A., Davis, V. G., Atkins, A. S., Krishnan, K., Fox, K. H., Harvey, P. D., & Keefe, R. S. E. (2014) · Journal of Visualized Experiments · doi:10.3791/51405 · Cited by 25 · see citing works
Self-citationTanaka, M., Kunugi, A., Suzuki, A., Suzuki, N., Suzuki, M., & Kimura, H. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.479 · Cited by 24 · see citing works
Katona, L., Bitter, I., & Czobor, P. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01636-9 · Cited by 24 · see citing works
Stone, W. S., Mesholam‐Gately, R. I., Giuliano, A. J., Woodberry, K. A., Addington, J., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Mathalon, D. H., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.02.003 · Cited by 24 · see citing works
Self-citationTowards Medication-Enhancement of Cognitive Interventions in Schizophrenia
Chou, H., Twamley, E. W., & Swerdlow, N. R. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_4 · Cited by 23 · see citing works
Harvey, P. D., Horan, W. P., Atkins, A. S., Stevens, H. B., Welch, M., Yuan, J., Patterson, T. L., Narasimhan, M., & Keefe, R. S. E. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.08.010 · Cited by 22 · see citing works
Self-citationAmphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults
Chou, H., Talledo, J., Lamb, S. N., Thompson, W. K., & Swerdlow, N. R. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2948-x · Cited by 22 · see citing works
Hou, W., Zhou, F., Wang, Q., Li, H., Qin, X., Ding, Y., Dong, F., Bo, Q., Li, A., Zhang, L., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02994-w · Cited by 21 · see citing works
Towards remote digital phenotyping of cognition in schizophrenia
Guimond, S., Keshavan, M. S., & Torous, J. B. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.04.016 · Cited by 21 · see citing works
Predicting work outcome in patients with schizophrenia: Influence of IQ decline
Sumiyoshi, C., Fujino, H., Yamamori, H., Kudo, N., Azechi, H., Fujimoto, M., Yasuda, Y., Ohi, K., Sumiyoshi, T., & Hashimoto, R. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.05.042 · Cited by 20 · see citing works
Applicability of the MATRICS Consensus Cognitive Battery in Singapore
Rapisarda, A., Lim, T. F., Lim, M., Collinson, S. L., Kraus, M., & Keefe, R. S. E. (2013) · The Clinical Neuropsychologist · doi:10.1080/13854046.2012.762120 · Cited by 19 · see citing works
Self-citationHarvey, P. D., Khan, A., Atkins, A. S., & Keefe, R. S. E. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.01.045 · Cited by 19 · see citing works
Self-citationEffects of sertindole on cognition in clozapine‐treated schizophrenia patients
Nielsen, R. E., Levander, S. E., Thode, D., & Nielsen, J. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01840.x · Cited by 19 · see citing works
Wu, Z., Liu, Q., Zhang, Y., Guan, X., Xiu, M., & Zhang, X. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab065 · Cited by 18 · see citing works
Rheenen, T. E. V., & Rossell, S. L. (2014) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617714000484 · Cited by 18 · see citing works
Cognition in schizophrenia – a systematic review
Nielsen, R. E. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.09.004 · Cited by 17 · see citing works
Horiguchi, M., Miyauchi, M., Neugebauer, N. M., Oyamada, Y., & Meltzer, H. Y. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.08.040 · Cited by 17 · see citing works
Giordano, G. M., Palumbo, D., Mucci, A., Ventura, J., Giuliani, L., Perrottelli, A., Bucci, P., Rocca, P., Rossi, A., Bertolino, A., et al. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.01.029 · Cited by 16 · see citing works
Sumiyoshi, C., Harvey, P. D., Takaki, M., Okahisa, Y., Sato, T., Sora, I., Nuechterlein, K. H., Subotnik, K. L., & Sumiyoshi, T. (2015) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2015.07.003 · Cited by 15 · see citing works
Use of Translational Pharmacodynamic Biomarkers in Early-Phase Clinical Studies for Schizophrenia
English, B. A., Thomas, K. L. H., Johnstone, J., Bazih, A., Gertsik, L., & Ereshefsky, L. (2013) · Biomarkers in Medicine · doi:10.2217/bmm.13.135 · Cited by 15 · see citing works
Kumar, S., Mulsant, B. H., Tsoutsoulas, C., Ghazala, Z., Voineskos, A. N., Bowie, C. R., & Rajji, T. K. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4547 · Cited by 14 · see citing works
Conducting clinical studies targeting cognition in psychiatry: guiding principles and design
Rheenen, T. E. V., Lewandowski, K. E., Lipschitz, J. M., & Burdick, K. E. (2018) · CNS Spectrums · doi:10.1017/s1092852918001074 · Cited by 14 · see citing works
Fu, S., Czajkowski, N. O., & Torgalsbøen, A. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.06.016 · Cited by 13 · see citing works
Watson, M. R., Traczewski, N., Dunghana, S., Boroujeni, K. B., Neumann, A. R., Wen, X., & Womelsdorf, T. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.09.566422 · Cited by 12 · see citing works
- Authors
- Buchanan, R. W., Keefe, R. S. E., Umbricht, D., Green, M. F., Laughren, T., & Marder, S. R.
- Affiliations
- University of Maryland, Baltimore (US)
- Duke Medical Center (US)
- F. Hoffmann-La Roche AG (CH)
- University of California, Los Angeles (US)
- United States Food and Drug Administration (US)
- Corresponding author
- Buchanan, R. W.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-04-21
- Volume
- 37
- Issue
- 6
- Pages
- 1209-1217
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC3196938
- OpenAlex
- W2126154566
- Cited by
- 154
- References
- 38
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 10 · 2023: 8 · 2022: 4 · 2021: 6 · 2020: 6 · 2019: 10 · 2018: 7 · 2017: 4 · 2016: 11 · 2015: 19 · 2014: 14 · 2013: 20 · 2012: 10
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Schizophrenia Bulletin (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- CHDI Foundation
- F. Hoffmann-La Roche
- Dainippon Sumitomo Pharma
- H. Lundbeck A/S
- National Institutes of Health (n01mh022006-001)
- U.S. Public Health Service (HHSN278 200441003C)
- National Institute of Mental Health (MH22006)
- Cilag
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- nootropic drugs
- MeSH terms
- Adult, Clinical Trials as Topic, Cognition, Humans, National Institute of Mental Health (U.S.), Neuropsychological Tests, Research Design, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, United States, United States Food and Drug Administration, Guidelines as Topic, Nootropic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
